Global Pharmaceutical Contract Manufacturing Industry

  • March 2012
  • -
  • Global Industry Analysts
  • -
  • 221 pages

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Million by the following Dosage Forms: Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid Dosage Forms (Syrups and Suspensions). The report provides separate comprehensive analytics for the USA, Canada, Japan, Europe, Asia-Pacific and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 82 companies including many key and niche players such as Althea Technologies, Catalent Pharma Solutions, Dishman Pharmaceuticals and Chemicals Ltd, HAUPT Pharma AG, Jubilant Life Sciences Limited, Kemwell Pvt. Ltd, NextPharma, Nipro Corp., Patheon, Inc., Penn Pharmaceutical Services Ltd. and Royal DSM N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table Of Contents





I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
Recession Lashes Global Pharmaceutical Contract Manufacturing
Industry II-1
Recession Bodes Better Long Term Prospects II-1
Major Changes Imperative to Capitalize on Brighter Future
Prospects II-2
Asia Dominates Regional Growth, North America Retains Position
as Largest Market II-2
Solid Dosage Form Continues to Remain Popular Among Pharma
Contract Manufacturers II-3
Generic Drugs: A Business Case for PCM’s of Solid Drugs II-3
Biopharmaceutical Contract Manufacturing Market to Surge II-4
PCM - A Highly Fragmented Industry II-4
Table 1: Leading Players in the Global Pharmaceutical
Contract Manufacturing Market (2009): Percentage Breakdown of
Revenues for Catalent, Patheon, Vetter, Baxter, Famar and
Others (includes corresponding Graph/Chart) II-4
Key Drivers of the Market II-5

2. SERVICE OVERVIEW II-6
Introduction II-6
Injectables (injections, vials, and IV solutions) II-6
Solid Dosage Forms (SDFs) (Tablets and Capsules) II-6
Liquid Dosage Forms (LDFs) (Syrups and Suspensions) II-7
An Insight into the Rise of Pharmaceutical Contract Manufacturing II-7
A Focus on Bio-Manufacturing II-8

3. MARKET DYNAMICS II-9
Outsourcing Emerges as a Strategic Priority for Pharmaceutical
Companies II-9
APIs Account for a Larger Share, While Finished Dosage Would
Drive Growth of PCM Market II-9
Is One Stop the Ideal Form of Contract Manufacturing? II-9
Virtual Pharma vs. Blockbuster Model II-10
Increased Scrutiny: A Case of Concern for the Industry II-10
Investment Risks in Pharmaceutical Contract II-10
Quality Assurance Risk II-10
Drug Development Risk II-11
Acquisition Risk II-11
Client Dependency Risk II-11

4. RECENT INDUSTRY ACTIVITY II-12
Catalent Pharma Enters into a License Agreement with Pantec AG II-12
Glatt Unveils New cGMP Capacity for Tablet and Capsule Production II-12
MDS Divests MDS Pharma Services II-12
Merck Closes Avecia Acquisition II-13
Watson Acquires Eden Biopharm II-13
Claris Life Sciences to Expand Drug Supply Services II-13
Ranbaxy Inks Agreement to Take Over Assets of Biovel Lifesciences II-13
Indoco to Enhance CRAMS Capabilities II-14
AlphaRx Inks API Supply Agreement with Venturepharm II-15
Alfresca Pharma to Enhance Contract Manufacturing Capabilities II-15
Jubilant Realigns Newly Acquired Companies HollisterStier and
DRAXIS II-15
Bausch and Lomb Acquires Assets of Tubilux Pharma II-15
Sigma Pharmaceuticals to Acquire Pharmaceutical Brands and
Manufacturing Facility of BMS II-16
Walter Street Acquires AAIPharma’s Pharmaceutical Development
Division II-16
Lonza Plans Acquisition of Patheon for US$ 460 Million II-17
Daiichi Sankyo and CMIC Ink Pact for Transferring Shizuoka Plant II-17
Novasep Acquires Henogen II-18
First Boston Pharma Buys NutraMax Products II-18
Boehringer Ingelheim Renews Chemistry Services Agreement with
Dalton Pharma II-19
Selexys Appoints Cytovance as a Contract Manufacturer for
Crohn’s Disease Drug II-19

5. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORICPERSPECTIVE BUILDER II-20
Fresenius Kabi Pharmaceuticals Acquires APP Pharmaceuticals II-20
Recordati Enters into an Agreement to Acquire Yeni Ilac II-20
Laureate Pharma Inks a Contract Manufacturing Pact with Tolera
Therapeutics II-20
Akorn Signs Exclusive Contract Manufacturing Agreement II-20
Haupt Pharma Merges with Wülfing Pharma and AMAREG II-21
United Drug Announces Acquisition of Sharp Corporation II-21
Oso Biopharmaceuticals to Acquire Albuquerque Injectables
Business II-21
Dr. Reddy's Laboratories Acquires PCM Business of BASF II-21
Medikalla and Probio to Form a New Joint Venture Finbio II-22
Dragenopharm Merge With Swiss Caps and Form AENOVA II-22
Akorn Signs Contract Manufacturing Pact with a Leading US
Pharmaceutical Firm II-23
Jubilant Acquires Draxis for US$ 253 Million II-23
JHP Acquires Assets of King Pharmaceuticals II-23
NextPharma Acquires Bioserv Corporation II-23
PharmAthene to Acquire Avecia’s Biodefense Vaccine Operations II-24
Bioserv Enters into an Outsourcing Agreement with BioLife
Solutions II-24
Eden Biodesign and Stealthyx Therapeutics Ink an Agreement II-25
NPIL Pharma to Expand HPS Sites in Scotland II-25
Dishman Pharma Installs New API Facilities II-25
Patheon Divests Niagara-Burlington Manufacturing Business to
Pharmetics II-26
Jubilant Organosys Acquires Hollister-Stier Laboratories II-26
Hikma Pharmaceuticals Acquires Thymoorgan GmbH Pharmazie II-26
Meda Acquires Recip II-27
Keata Pharma Acquires Pfizer’s Production Facility in Canada II-27
STADA Acquires MAKIZ II-28
Nextpharma to Expand its Cytostatics Production Facility II-28
Haupt Pharma Establishes Production Facility in Malta II-29
Kemwell Pockets Pfizer’s Uppsala Sweden Based Manufacturing Plant II-29
Crucell and DSM Biologics Enter into a Licensing Agreement
with UMN Pharma II-29
Lannett Inks a Multi-Product Contract Manufacturing Agreement
with Wintac II-30
ATOZ Establishes Soft Gelatin Manufacturing Facility in
Himachal Pradesh, India II-30
BASF Buys Orgamol SA II-30
Federa Completes Construction of Prefilled Syringes Facility II-30
BioProgress PLC Signs an Agreement with Custom Pharmaceuticals II-31
Safeguard Scientifics Acquires Laureate II-31

6. FOCUS ON SELECT GLOBAL PLAYERS II-32
Althea Technologies (USA) II-32
Catalent Pharma Solutions (USA) II-32
Dishman Pharmaceuticals and Chemicals Ltd (India) II-32
HAUPT Pharma AG (Germany) II-32
Jubilant Life Sciences Limited (India) II-32
Kemwell Pvt. Ltd (India) II-33
NextPharma (UK) II-33
Nipro Corp. (Japan) II-33
Patheon, Inc. (Canada) II-33
Penn Pharmaceutical Services Ltd. (UK) II-34
Royal DSM N.V. (The Netherlands) II-34

7. GLOBAL MARKET PERSPECTIVE II-35
Table 2: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets Independently Analyzed with Annual Revenue in US$
Million for the Years 2009 through 2017 (includes
corresponding Graph/Chart) II-35

Table 3: World Historic Review for Pharmaceutical Contract
Manufacturing by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for the
Years 2003 through 2008 (includes corresponding Graph/Chart) II-36

Table 4: World 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Geographic Region - Percentage Breakdown of
Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets for the Years 2003, 2011 and 2017
(includes corresponding Graph/Chart) II-37

Table 5: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing of Injectables
(Injections, Vials and Intravenous Solutions) by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of
World Markets Independently Analyzed with Annual Revenue
Figures in US$ Million for the Years 2009 through 2017
(includes corresponding Graph/Chart) II-38

Table 6: World Historic Review for Pharmaceutical Contract
Manufacturing of Injectables (Injections, Vials and Intravenous
Solutions) by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific and Rest of World Markets Independently Analyzed
with Annual Revenue Figures in US$ Million for the Years 2003
through 2008 (includes corresponding Graph/Chart) II-39

Table 7: World 15-Year Perspective for Pharmaceutical Contract
Manufacturing of Injectables (Injections, Vials and Intravenous
Solutions) by Geographic Region - Percentage Breakdown of
Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets for the Years 2003, 2011 and 2017
(includes corresponding Graph/Chart) II-40

Table 8: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing of Solid Dosage Forms
(Tablets and Capsules) by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for the
Years 2009 through 2017 (includes corresponding Graph/Chart) II-41

Table 9: World Historic Review for Pharmaceutical Contract
Manufacturing of Solid Dosage Forms (Tablets and Capsules) by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for the Years 2003 through 2008
(includes corresponding Graph/Chart) II-42

Table 10: World 15-Year Perspective for Pharmaceutical
Contract Manufacturing of Solid Dosage Forms (Tablets and
Capsules) by Geographic Region - Percentage Breakdown of
Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets for the Years 2003, 2011 and 2017
(includes corresponding Graph/Chart) II-43

Table 11: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing of Liquid Dosage Forms
(Syrups and Suspensions) by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for the Years 2009 through 2017 (includes
corresponding Graph/Chart) II-44

Table 12: World Historic Review for Pharmaceutical Contract
Manufacturing of Liquid Dosage Forms (Syrups and Suspensions) by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for the Years 2003 through 2008
(includes corresponding Graph/Chart) II-45

Table 13: World 15-Year Perspective for Pharmaceutical
Contract Manufacturing of Liquid Dosage Forms (Syrups and
Suspensions) by Geographic Region - Percentage Breakdown of
Annual Revenues for US, Canada, Japan, Europe, Asia- Pacific
and Rest of World Markets for the Years 2003, 2011 and 2017
(includes corresponding Graph/Chart) II-46


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Trends III-1
Pharma Companies Increasingly Outsource Manufacturing Activity III-1
Injectables Segment Witnesses Upward Growth Trend III-1
Competitive Landscape III-1
B.Market Analytics III-2
Table 14: US Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing by Dosage Form -
Injectables (Injections, Vials and Intravenous Solutions),
Solid Dosage Forms (Tablets and Capsules) and Liquid Dosage
Forms (Syrups and Suspensions) Independently Analyzed with
Annual Revenue Figures in US$ Million for the Years 2009
through 2017 (includes corresponding Graph/Chart) III-2

Table 15: US Historic Review for Pharmaceutical Contract
Manufacturing by Dosage Form - Injectables (Injections,
Vials and Intravenous Solutions), Solid Dosage Forms (Tablets
and Capsules) and Liquid Dosage Forms (Syrups and Suspensions)
Independently Analyzed with Annual Revenue Figures in US$
Million for the Years 2003 through 2008 (includes
corresponding Graph/Chart) III-3

Table 16: US 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Dosage Form - Percentage Breakdown of
Annual Revenues for Injectables (Injections, Vials and
Intravenous Solutions), Solid Dosage Forms (Tablets and
Capsules) and Liquid Dosage Forms (Syrups and Suspensions) for
the Years 2003, 2011 and 2017 (includes corresponding
Graph/Chart) III-4

2. CANADA III-5
Market Analytics III-5
Table 17: Canadian Recent Past, Current and Future Analysis
for Pharmaceutical Contract Manufacturing by Dosage Form -
Injectables (Injections, Vials and Intravenous Solutions),
Solid Dosage Forms (Tablets and Capsules) and Liquid Dosage
Forms (Syrups and Suspensions) Independently Analyzed with
Annual Revenue Figures in US$ Million for the Years 2009
through 2017 (includes corresponding Graph/Chart) III-5

Table 18: Canadian Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid Dosage Forms (Syrups and
Suspensions) Independently Analyzed with Annual Revenue
Figures in US$ Million for the Years 2003 through 2008
(includes corresponding Graph/Chart) III-6

Table 19: Canadian 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Dosage Form - Percentage Breakdown
of Annual Revenues for Injectables (Injections, Vials and
Intravenous Solutions), Solid Dosage Forms (Tablets and
Capsules) and Liquid Dosage Forms (Syrups and Suspensions) for
the Years 2003, 2011 and 2017 (includes corresponding
Graph/Chart) III-7

3. JAPAN III-8
A.Market Analysis III-8
Impact of Contract Manufacturing on Japanese Pharmaceutical
Sector III-8
B.Market Analytics III-8
Table 20: Japanese Recent Past, Current and Future Analysis
for Pharmaceutical Contract Manufacturing by Dosage Form -
Injectables (Injections, Vials and Intravenous Solutions),
Solid Dosage Forms (Tablets and Capsules) and Liquid Dosage
Forms (Syrups and Suspensions) Independently Analyzed with
Annual Revenue Figures in US$ Million for the Years 2009
through 2017 (includes corresponding Graph/Chart) III-8

Table 21: Japanese Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid Dosage Forms (Syrups and
Suspensions) Independently Analyzed with Annual Revenue
Figures in US$ Million for the Years 2003 through 2008
(includes corresponding Graph/Chart) III-9

Table 22: Japanese 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Dosage Form - Percentage Breakdown
of Annual Revenues for Injectables (Injections, Vials and
Intravenous Solutions), Solid Dosage Forms (Tablets and
Capsules) and Liquid Dosage Forms (Syrups and Suspensions) for
the Years 2003, 2011 and 2017 (includes corresponding
Graph/Chart) III-10

4. EUROPE III-11
A.Market Analysis III-11
Injectables Segment Offers Promising Potential III-11
Competitive Scenario III-11
B.Market Analytics III-12
Table 23: European Recent Past, Current and Future Analysis
for Pharmaceutical Contract Manufacturing by Dosage Form -
Injectables (Injections, Vials and Intravenous Solutions),
Solid Dosage Forms (Tablets and Capsules) and Liquid Dosage
Forms (Syrups and Suspensions) Independently Analyzed with
Annual Revenue Figures in US$ Million for the Years 2009
through 2017 (includes corresponding Graph/Chart) III-12

Table 24: European Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid Dosage Forms (Syrups and
Suspensions) Independently Analyzed with Annual Revenue
Figures in US$ Million for the Years 2003 through 2008
(includes corresponding Graph/Chart) III-13

Table 25: European 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Dosage Form - Percentage Breakdown
of Annual Revenues for Injectables (Injections, Vials and
Intravenous Solutions), Solid Dosage Forms (Tablets and
Capsules) and Liquid Dosage Forms (Syrups and Suspensions) for
the Years 2003, 2011 and 2017 (includes corresponding
Graph/Chart) III-14

5. ASIA-PACIFIC III-15
A.Market Analysis III-15
Trends III-15
Asia - Emerging Hub for Contract Manufacturing III-15
Upbeat Market for Pharmaceutical Contract Manufacturing III-15
Competitive Scenario III-15
China III-15
China’s Pharmaceutical Outsourcing Industry Outlives
Recessionary Effects III-15
India III-16
Pharmaceutical Outsourcing Market Puffs Up III-16
B.Market Analytics III-17
Table 26: Asia-Pacific Recent Past, Current and Future
Analysis for Pharmaceutical Contract Manufacturing by Dosage
Form - Injectables (Injections, Vials and Intravenous
Solutions), Solid Dosage Forms (Tablets and Capsules) and
Liquid Dosage Forms (Syrups and Suspensions) Independently
Analyzed with Annual Revenue Figures in US$ Million for the
Years 2009 through 2017 (includes corresponding Graph/Chart) III-17

Table 27: Asia-Pacific Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid Dosage Forms (Syrups and
Suspensions) Independently Analyzed with Annual Revenue
Figures in US$ Million for the Years 2003 through 2008
(includes corresponding Graph/Chart) III-18

Table 28: Asia-Pacific 15-Year Perspective for
Pharmaceutical Contract Manufacturing by Dosage Form -
Percentage Breakdown of Annual Revenues for Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid Dosage Forms (Syrups and
Suspensions) for the Years 2003, 2011 and 2017 (includes
corresponding Graph/Chart) III-19

6. REST OF WORLD III-20
Market Analytics III-20
Table 29: Rest of World Recent Past, Current and Future
Analysis for Pharmaceutical Contract Manufacturing by Dosage
Form - Injectables (Injections, Vials and Intravenous
Solutions), Solid Dosage Forms (Tablets and Capsules) and
Liquid Dosage Forms (Syrups and Suspensions) Independently
Analyzed with Annual Revenue Figures in US$ Million for the
Years 2009 through 2017 (includes corresponding Graph/Chart) III-20

Table 30: Rest of World Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid Dosage Forms (Syrups and
Suspensions) Independently Analyzed with Annual Revenue
Figures in US$ Million for the Years 2003 through 2008
(includes corresponding Graph/Chart) III-21

Table 31: Rest of World 15-Year Perspective for
Pharmaceutical Contract Manufacturing by Dosage Form -
Percentage Breakdown of Annual Revenues for Injectables
(Injections, Vials and Intravenous Solutions), Solid Dosage
Forms (Tablets and Capsules) and Liquid Dosage Forms (Syrups and
Suspensions) for the Years 2003, 2011 and 2017 (includes
corresponding Graph/Chart) III-22


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 82 (including Divisions/Subsidiaries - 87)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 29
Canada 6
Japan 3
Europe 33
France 3
Germany 8
The United Kingdom 9
Italy 4
Rest of Europe 9
Asia-Pacific (Excluding Japan) 16
------------------------------------------

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Connected Living

Connected Living

  • $ 15 000
  • Industry report
  • April 2014
  • by Frost & Sullivan

The research service sets the stage for visionary thinking by identifying and analyzing one of the significant Mega Trends—Connected Living—where ICT-enabled services are being offered to consumers ...

Commercial Vehicles 2020 Vision

Commercial Vehicles 2020 Vision

  • $ 15 000
  • Industry report
  • May 2014
  • by Frost & Sullivan

Green, Safe, and Connected Medium-heavy Trucks to Drive Future Freight Mobility Some of the key trends for OEMs globally are powertrains gaining strength in customer retention strategies, and vehicle platforms ...

Analysis of the Global Subsea Equipment Market

Analysis of the Global Subsea Equipment Market

  • $ 10 000
  • Industry report
  • June 2014
  • by Frost & Sullivan

With Advancements in Technology, Migration to Deep Waters is Increasing Steadily With new fields being discovered in the offshore regions, the declining recovery rate, and production from ageing fields, ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.